DeCure for Self-limited epilepsy with centrotemporal spikes
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for self-limited epilepsy with centrotemporal spikes — screening already-approved drugs against its 25-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSelf-limited epilepsy with centrotemporal spikes maps to a 25-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for self-limited epilepsy with centrotemporal spikes is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel beta subunit 1 (SCN1B) — SCN1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7W9K · 2.2 Å · ligand O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine (P5S). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Epilepsia · 2009 · 71 citations
Benign epilepsy with centrotemporal spikes
AbstractBenign epilepsy with centrotemporal spikes (BECTS) is a common disorder in childhood. After a brief overview of BECTS, a review of the data in favor of treatment with anticonvulsant medications is followed by the data indicating that treatment is not indicated. Some children appear to have cognitive consequences from BECTS. The parents and children with BECTS require a full discussion of the pros and cons of treatment, but based on data available at this time, it is concluded that treatment is generally not indicated for most patients. Future research may lead to changes in the recommendations.
Journal of Clinical Neurophysiology · 2025 · 0 citations
Prevalence and Functional Significance of 14 and 6 Hz Positive Spikes in Self-Limited Epilepsy With Centrotemporal Spikes: A Case–Control Study
AbstractPURPOSE: To investigate the prevalence and functional significance of 14 and 6 Hz positive spikes (PS) in children with Self-limited Epilepsy with Centrotemporal spikes and explore their potential correlation with clinical features and neurophysiological mechanisms. METHODS: Our study included 52 pediatric Self-limited Epilepsy with Centrotemporal spikes patients and 52 age-matched controls who underwent ≥48-hour video-EEG monitoring in the epilepsy monitoring unit at Oishei Children's Hospital from 2016 to 2024. EEGs were reviewed by blinded epileptologists to identify the presence, localization, and lateralization of 14 and 6 Hz PS. RESULTS: Fourteen and 6 Hz PS were detected in 80.8% ( n = 42) of SeLECTs patients versus 0% of controls ( P < 0.001). No significant lateralization correlation was found between PS and centrotemporal spikes ( P = 0.651); only 28.6% of PS cases matched centrotemporal spikes lateralization. CONCLUSIONS: This study demonstrates a significantly higher prevalence of 14 and 6 Hz PS in children with Self-limited Epilepsy with Centro-temporal spikes. Their high prevalence and similar age-dependent expression and sleep-related activation suggest that PS may reflect developmental immaturity in thalamocortical networks, immature corticolimbic circuits, and heightened cortical excitability. These findings challenge the traditional view of PS as benign and support their potential role in thalamocortical dysregulation in self-limited childhood epilepsies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
